The Experts below are selected from a list of 723 Experts worldwide ranked by ideXlab platform
Cheryl A. London - One of the best experts on this subject based on the ideXlab platform.
-
Targeted Therapies in Veterinary Oncology.
Veterinary Clinics of North America-small Animal Practice, 2019Co-Authors: Priya Londhe, Megan Gutwillig, Cheryl A. LondonAbstract:Advances in molecular biology have permitted a much more detailed understanding of cellular dysfunction at the molecular and genetic levels in cancer cells. This has resulted in the identification of novel targets for therapeutic intervention, including proteins that regulate signal transduction, gene expression, and protein turnover. In many instances, small molecules are used to disrupt the function of these targets, often through competitive inhibition of ATP binding or the prevention of necessary protein-protein interactions. More than 40 small molecule inhibitors are now approved to treat a variety of human cancers, substantially impacting patient outcomes.
-
response evaluation criteria for solid tumours in dogs v1 0 a Veterinary cooperative Oncology group vcog consensus document
Veterinary and Comparative Oncology, 2015Co-Authors: Sandra Nguyen, Douglas H Thamm, David M Vail, Cheryl A. LondonAbstract:In Veterinary medical Oncology, there is currently no standardized protocol for assessing response to therapy in solid tumours. The lack of such a formalized guideline makes it challenging to critically compare outcome measures across various treatment protocols. The Veterinary Cooperative Oncology Group (VCOG) membership consensus document presented here is based on the recommendations of a subcommittee of American College of Veterinary Internal Medicine (ACVIM) board-certified Veterinary oncologists. This consensus paper has used the human response evaluation criteria in solid tumours (RECIST v1.1) as a framework to establish standard procedures for response assessment in canine solid tumours that is meant to be easy to use, repeatable and applicable across a variety of clinical trial structures in Veterinary Oncology. It is hoped that this new canine RECIST (cRECIST v1.0) will be adopted within the Veterinary Oncology community and thereby facilitate the comparison of current and future treatment protocols used for companion animals with cancer.
-
small molecule inhibitors in Veterinary Oncology practice
Veterinary Clinics of North America-small Animal Practice, 2014Co-Authors: Cheryl A. LondonAbstract:Recent advances in molecular biology have permitted the identification and characterization of specific abnormalities regarding cell signaling and function in cancer cells. Proteins that are found to be dysregulated in cancer cells can serve as relevant targets for therapeutic intervention. Although there are several approaches to block proteins that contribute to cellular dysfunction, the one most commonly used involves a class of therapeutics called small molecule inhibitors. Such inhibitors work by disrupting critical pathways/processes in cancer cells, thereby preventing their ability to grow and survive.
-
Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs
BMC Veterinary Research, 2012Co-Authors: Matthew George Sherger, Cheryl A. London, William C. Kisseberth, Susan E. Olivo-marston, Tracey L. PapenfussAbstract:Background Myeloid derived suppressor cells (MDSCs) are a recently described population of immune cells that significantly contribute to the immunosuppression seen in cancer patients. MDSCs are one of the most important factors that limit the efficacy of cancer immunotherapy (e.g. cancer vaccines) and MDSC levels are increased in cancer in multiple species. Identifying and targeting MDSCs is actively being investigated in the field of human Oncology and is increasingly being investigated in Veterinary Oncology. The treatment of canine cancer not only benefits dogs, but is being used for translational studies evaluating and modifcying candidate therapies for use in humans. Thus, it is necessary to understand the immune alterations seen in canine cancer patients which, to date, have been relatively limited. This study investigates the use of commercially available canine antibodies to detect an immunosuppressive (CD11blow/CADO48low) cell population that is increased in the peripheral blood of tumor-bearing dogs.
-
response evaluation criteria for peripheral nodal lymphoma in dogs v1 0 a Veterinary cooperative Oncology group vcog consensus document
Veterinary and Comparative Oncology, 2010Co-Authors: David M Vail, Chand Khanna, G M Michels, Kimberly Anne Selting, Cheryl A. LondonAbstract:Standardized assessment of response to therapy for lymphoma in dogs is lacking, making critical comparisons of treatment protocols difficult. This Veterinary Cooperative Oncology Group (VCOG) consensus document, based on the recommendat ionsof as ubcommittee of ACVIM board-certif ied Veterinary oncologists, was unanimously adopted at the 29th Annual Conference of the Veterinary Cancer Society (VCS) by the VCOG membership. It has integrated guidance from the response assessment criteria established for lymphoma in human patients using standards available in routine Veterinary Oncology practices that are simple, repeatable and consistently applicable. These guidelines are intended only for use in dogs, where peripheral lymphadenopathy represents the principal component of their disease and as such do not critically assess extranodal disease (e.g., primary cutaneous, central nervous system, gastrointestinal). It is hoped these guidelines will be widely adopted and serve to facilitate the comparisonof currentand future treatment protocolsused in the therapy of dogs.
David M Vail - One of the best experts on this subject based on the ideXlab platform.
-
Conduct, Oversight, and Ethical Considerations of Clinical Trials in Companion Animals with Cancer: Report of a Workshop on Best Practice Recommendations
Journal of Veterinary Internal Medicine, 2016Co-Authors: Rodney L. Page, David M Vail, P. Baneux, Lili Duda, Patricia N. Olson, L. Anestidou, N. Dybdal, G. Golab, W. Shelton, M. SalgallerAbstract:Development of effective and safe treatments for companion animals with cancer requires the collaboration of numerous animal health professionals and the full engagement of animal owners. Establishing ‘Best Practice Recommendations’ for clinical trials in Veterinary Oncology represents an important step toward meeting the goal of rigorous clinical trial design and conduct that is required to establish valid evidence. Likewise, optimizing patient welfare and owner education and advocacy is crucial to meet the unique ethical obligations to both owners and animals enrolled in these clinical trials and to ensure trust in the team conducting the research. To date, ‘Best Practice Recommendations’ for clinical trial conduct have not been reported for Veterinary Oncology. This document summarizes the consensus of a workshop held in November, 2014 to identify relevant ethical principles and to ensure responsible conduct of clinical research in companion animals with cancer. It is intended as a working document that will be updated as advances in science and ethical considerations require. To the extent possible, existing guidelines for the conduct and oversight of clinical trials in humans have been adapted for Veterinary trials to avoid duplicative effort and to facilitate integration of clinical trials such that translational research with benefits for both companion animals and humans are encouraged.
-
response evaluation criteria for solid tumours in dogs v1 0 a Veterinary cooperative Oncology group vcog consensus document
Veterinary and Comparative Oncology, 2015Co-Authors: Sandra Nguyen, Douglas H Thamm, David M Vail, Cheryl A. LondonAbstract:In Veterinary medical Oncology, there is currently no standardized protocol for assessing response to therapy in solid tumours. The lack of such a formalized guideline makes it challenging to critically compare outcome measures across various treatment protocols. The Veterinary Cooperative Oncology Group (VCOG) membership consensus document presented here is based on the recommendations of a subcommittee of American College of Veterinary Internal Medicine (ACVIM) board-certified Veterinary oncologists. This consensus paper has used the human response evaluation criteria in solid tumours (RECIST v1.1) as a framework to establish standard procedures for response assessment in canine solid tumours that is meant to be easy to use, repeatable and applicable across a variety of clinical trial structures in Veterinary Oncology. It is hoped that this new canine RECIST (cRECIST v1.0) will be adopted within the Veterinary Oncology community and thereby facilitate the comparison of current and future treatment protocols used for companion animals with cancer.
-
Veterinary Oncology clinical trials design and implementation
Veterinary Journal, 2015Co-Authors: Douglas H Thamm, David M VailAbstract:There has been a recent increase in interest among veterinarians and the larger biomedical community in the evaluation of novel cancer therapies in client-owned (pet) animals with spontaneous cancer. This includes novel drugs designed to be Veterinary therapeutics, as well as agents for which data generated in animals with tumors may inform human clinical trial design and implementation. An understanding of the process involved in moving a therapeutic agent through the stages of clinical evaluation is critical to the successful implementation of clinical investigations, as well as interpretation of the Veterinary Oncology literature. This review outlines considerations in the design and conduct of the various phases of Oncology clinical trials, along with recent adaptations/modifications of these basic designs that can enhance the generation of timely and meaningful clinical data.
-
Comparative Oncology – the North American experience
BMC Proceedings, 2013Co-Authors: David M VailAbstract:Comparative Oncology can be used to describe a discipline that integrates the study of naturally occurring cancers in animals into studies of human cancer biology and therapy. The term is most often used when referring to the study of cancers seen in companion (pet) animals. Cancers in companion species are well suited to uniquely inform investigations of cancer biology and drug development. Clinical trials in Veterinary Oncology have gained interest and focus over the last decade, with both Veterinary and comparative Oncology drug development leading the effort. There have also been a growing number of consortia and cooperative groups that have functioned successfully by uniting multiinstitutional efforts, advocating for Veterinary clinical trials, and emphasizing the synergy between basic science and clinical progress. With support from clients who are motivated to seek advanced care for their pets and to enroll them in investigational trials that offer new therapies, clinical research in Veterinary Oncology is growing in scope and importance. Oncology clinical trials attempt to answer questions and find better ways to prevent, diagnose, or treat cancer. Their model is different from trials involving infectious or even chronic diseases because the risks involved have greater morbidity and mortality. Traditional drug development follows a strict, step-wise paradigm that begins with a phase I dose-finding trial, followed by a phase II efficacy/activity trial, and concludes with a phase III "pivotal" trial that pits a novel agent against or with the current standard of care (Table (Table1).1). Although Veterinary Oncology trials sometimes combine these concepts, their individual descriptions serve as the framework for new drug development. Clinical designs, pertinent endpoints and analyses, the process for drug approval, and clinical trial ethics will be explored in the following sections. Table 1 Goals of Phase I–III Clinical Trials
-
response evaluation criteria for peripheral nodal lymphoma in dogs v1 0 a Veterinary cooperative Oncology group vcog consensus document
Veterinary and Comparative Oncology, 2010Co-Authors: David M Vail, Chand Khanna, G M Michels, Kimberly Anne Selting, Cheryl A. LondonAbstract:Standardized assessment of response to therapy for lymphoma in dogs is lacking, making critical comparisons of treatment protocols difficult. This Veterinary Cooperative Oncology Group (VCOG) consensus document, based on the recommendat ionsof as ubcommittee of ACVIM board-certif ied Veterinary oncologists, was unanimously adopted at the 29th Annual Conference of the Veterinary Cancer Society (VCS) by the VCOG membership. It has integrated guidance from the response assessment criteria established for lymphoma in human patients using standards available in routine Veterinary Oncology practices that are simple, repeatable and consistently applicable. These guidelines are intended only for use in dogs, where peripheral lymphadenopathy represents the principal component of their disease and as such do not critically assess extranodal disease (e.g., primary cutaneous, central nervous system, gastrointestinal). It is hoped these guidelines will be widely adopted and serve to facilitate the comparisonof currentand future treatment protocolsused in the therapy of dogs.
Chand Khanna - One of the best experts on this subject based on the ideXlab platform.
-
the role of clinical trials in Veterinary Oncology
Veterinary Clinics of North America-small Animal Practice, 2014Co-Authors: Jenna H Burton, Chand KhannaAbstract:Clinical trials for companion animals are becoming more common and more accessible to pet owners as Veterinary oncologists seek to expand their knowledge of tumor biology in companion animal species and improve the way they diagnose and treat cancer for these animals. Many owners enroll their pets because they wish to participate in clinical cancer research that may ultimately benefit pets and people. Understanding the goals, benefits, and risks of clinical trials participation provides the knowledge needed by primary care veterinarians to counsel their clients as to whether clinical trial participation is a good choice for them and their pets.
-
response evaluation criteria for peripheral nodal lymphoma in dogs v1 0 a Veterinary cooperative Oncology group vcog consensus document
Veterinary and Comparative Oncology, 2010Co-Authors: David M Vail, Chand Khanna, G M Michels, Kimberly Anne Selting, Cheryl A. LondonAbstract:Standardized assessment of response to therapy for lymphoma in dogs is lacking, making critical comparisons of treatment protocols difficult. This Veterinary Cooperative Oncology Group (VCOG) consensus document, based on the recommendat ionsof as ubcommittee of ACVIM board-certif ied Veterinary oncologists, was unanimously adopted at the 29th Annual Conference of the Veterinary Cancer Society (VCS) by the VCOG membership. It has integrated guidance from the response assessment criteria established for lymphoma in human patients using standards available in routine Veterinary Oncology practices that are simple, repeatable and consistently applicable. These guidelines are intended only for use in dogs, where peripheral lymphadenopathy represents the principal component of their disease and as such do not critically assess extranodal disease (e.g., primary cutaneous, central nervous system, gastrointestinal). It is hoped these guidelines will be widely adopted and serve to facilitate the comparisonof currentand future treatment protocolsused in the therapy of dogs.
-
a survey of evidence in the journal of Veterinary internal medicine Oncology manuscripts from 1999 to 2007
Journal of Veterinary Internal Medicine, 2010Co-Authors: A Sahora, Chand KhannaAbstract:Objectives: To survey and monitor trends in evidence for Oncology manuscripts published in the Journal of Veterinary Internal Medicine (JVIM) between 1999 and 2007 based on an evidence-based medicine (EBM) standard. Methods: All Veterinary Oncology-related articles published in JVIM and 7 other high-impact journals from 1999 to 2007 were collected by database searches. Relevant manuscripts then were characterized including investigator affiliation, subject matter investigated, retrospective or prospective study design, manuscript type, and classifications of manuscripts using an EBM standard. Results: A total of 172 relevant Veterinary Oncology manuscripts were identified in JVIM between 1999 and 2007. The proportion of Oncology manuscripts published each year rose with the total number of manuscripts published in JVIM (mean, 13%; range, 8–15%). The author affiliations and subject matter were similar during this evaluation period. Case series represented the most common manuscript type (40%). With the exception of a progressive increase in prospective manuscripts and a reduction in case reports, no significant changes in the classification of manuscripts using EBM standards were seen. During this same period, Veterinary Oncology manuscripts published in 7 high-impact journals were associated with higher standards of evidence including prospective studies and randomized trials. Conclusions: The standards of evidence for Veterinary Oncology manuscripts published in JVIM have remained static between 1999 and 2007. This survey provides an informative benchmark for the state of evidence in previous JVIM Oncology manuscripts and may be useful in identifying specific opportunities that may raise the standards of evidence in future publications in JVIM.
Sandra Nguyen - One of the best experts on this subject based on the ideXlab platform.
-
response evaluation criteria for solid tumours in dogs v1 0 a Veterinary cooperative Oncology group vcog consensus document
Veterinary and Comparative Oncology, 2015Co-Authors: Sandra Nguyen, Douglas H Thamm, David M Vail, Cheryl A. LondonAbstract:In Veterinary medical Oncology, there is currently no standardized protocol for assessing response to therapy in solid tumours. The lack of such a formalized guideline makes it challenging to critically compare outcome measures across various treatment protocols. The Veterinary Cooperative Oncology Group (VCOG) membership consensus document presented here is based on the recommendations of a subcommittee of American College of Veterinary Internal Medicine (ACVIM) board-certified Veterinary oncologists. This consensus paper has used the human response evaluation criteria in solid tumours (RECIST v1.1) as a framework to establish standard procedures for response assessment in canine solid tumours that is meant to be easy to use, repeatable and applicable across a variety of clinical trial structures in Veterinary Oncology. It is hoped that this new canine RECIST (cRECIST v1.0) will be adopted within the Veterinary Oncology community and thereby facilitate the comparison of current and future treatment protocols used for companion animals with cancer.
William S Dernell - One of the best experts on this subject based on the ideXlab platform.
-
a review of sentinel lymph node evaluation and the need for its incorporation into Veterinary Oncology
Veterinary and Comparative Oncology, 2009Co-Authors: Joanne L Tuohy, J Milgram, Deanna R Worley, William S DernellAbstract:Being the first lymph node or nodes to which many primary tumours reliably drain, the disease status of the sentinel lymph node/s (SLN) is important in the prediction of survival. SLN identification and biopsy are critical in the staging of human cancers. The status of the SLN helps determine prognosis and shape treatment plans. SLN evaluation is currently not routinely performed in Veterinary Oncology, not even at specialty Oncology practices. Given the prognostic importance of lymph node involvement in tumours such as mammary gland carcinoma, osteosarcoma, synovial cell sarcoma and mast cell tumours, SLN evaluation should be incorporated into routine clinical practice so as to improve our clinical assessment of Veterinary oncologic patients.